Literature DB >> 10961714

Acid secretory changes in streptozotocin-diabetic rats: different responses to various secretagogues.

K Tashima1, M Nishijima, A Fujita, M Kubomi, K Takeuchi.   

Abstract

We examined gastric acid secretion in response to various stimuli in streptozotocin (STZ) induced diabetic rats and characterized the alteration of acid secretory responses in diabetic conditions. Animals were injected STZ (70 mg/kg, intraperitoneally) and used after five weeks of diabetes with blood glucose >350 mg/dl. Under urethane anesthesia, the experiment was performed in a chambered stomach or a whole stomach preparation, and the acid secretion was measured at pH 7.0 using a pH-stat method and by adding 100 mM NaOH. The acid secretion was stimulated by intravenous infusion of either histamine (4 mg/kg/hr), pentagastrin (60 microg/kg/hr), or carbachol (20 microg/kg/hr) or by intraluminal application of peptone solution (4%), or vagal electrical stimulation (2 msec, 3 Hz, 0.5 mA). In normal rats, acid secretion was increased in response to either histamine, pentagastrin, carbachol, peptone, or electrical vagal stimulation. In STZ diabetic rats, however, changes in acid secretion varied depending on the stimuli; the acid response to histamine remained unchanged, but the responses to vagal electrical stimulation or pentagastrin and carbachol were significantly decreased or enhanced, respectively, as compared to normal rats. Likewise, the acid response to peptone was also markedly enhanced in STZ-diabetic rats, and this response was significantly blocked by atropine and YM022 (a CCKB/gastrin antagonist) as well as famotidine in both normal and diabetic rats. Both pentagastrin and carbachol increased the luminal release of histamine in normal rats, and these responses were significantly augmented in STZ-diabetic rats. The altered acid response and histamine release induced by pentagastrin in STZ diabetic rats were partially reversed by daily injection of insulin. These results suggest that STZ-diabetic rats showed different changes in gastric acid secretion in response to various stimuli. The increased acid secretory response may be associated with an enhanced release of mucosal histamine, while the decreased response may be due to vagal neuropathy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10961714     DOI: 10.1023/a:1005556003938

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  23 in total

1.  Effects of S-0509, a novel CCKB/gastrin receptor antagonist, on acid secretion and experimental duodenal ulcers in rats.

Authors:  K Takeuchi; T Hirata; H Yamamoto; T Kunikata; M Ishikawa; Y Ishihara
Journal:  Aliment Pharmacol Ther       Date:  1999-01       Impact factor: 8.171

2.  Gastrin produces an immediate and dose-dependent histamine release preceding acid secretion in the totally isolated, vascularly perfused rat stomach.

Authors:  A K Sandvik; H L Waldum; P M Kleveland; B Schulze Søgnen
Journal:  Scand J Gastroenterol       Date:  1987-09       Impact factor: 2.423

Review 3.  Diabetes and the gastro-intestinal tract.

Authors:  D O'Reilly; R G Long
Journal:  Dig Dis       Date:  1987       Impact factor: 2.404

4.  Alterations in duodenal bicarbonate secretion and mucosal susceptibility to acid in diabetic rats.

Authors:  K Takehara; K Tashima; K Takeuchi
Journal:  Gastroenterology       Date:  1997-02       Impact factor: 22.682

5.  Role of nitric oxide in regulation of gastric acid secretion in rats: effects of NO donors and NO synthase inhibitor.

Authors:  S Kato; M Kitamura; R P Korolkiewicz; K Takeuchi
Journal:  Br J Pharmacol       Date:  1998-03       Impact factor: 8.739

6.  Endogenous nitric oxide in gastric alkaline response in the rat stomach after damage.

Authors:  K Takeuchi; T Ohuchi; S Okabe
Journal:  Gastroenterology       Date:  1994-02       Impact factor: 22.682

7.  Myenteric plexus in streptozotocin-treated rats. Neurochemical and histochemical evidence for diabetic neuropathy in the gut.

Authors:  J Lincoln; J T Bokor; R Crowe; S G Griffith; A J Haven; G Burnstock
Journal:  Gastroenterology       Date:  1984-04       Impact factor: 22.682

8.  YM022 [(R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo-5-phenyl- 1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea], a potent and selective gastrin/cholecystokinin-B receptor antagonist, prevents gastric and duodenal lesions in rats.

Authors:  A Nishida; Y Takinami; H Yuki; A Kobayashi; S Akuzawa; T Kamato; H Ito; M Yamano; Y Nagakura; K Miyata
Journal:  J Pharmacol Exp Ther       Date:  1994-09       Impact factor: 4.030

9.  Hypogastrinemia in streptozotocin diabetes with islet transplantation--reconstitution.

Authors:  P J Fabri; C J Weber; W R Gower; K Reemtsma
Journal:  J Surg Res       Date:  1983-05       Impact factor: 2.192

10.  Gastric acid secretion in streptozotocin-diabetic female rats.

Authors:  C Y Lin; G H Yeh; F C Hsu; S C Tsai; C P Lau; H F Pu; H L Yu; Y F Tung; P S Wang
Journal:  Chin J Physiol       Date:  1991       Impact factor: 1.764

View more
  3 in total

1.  Diabetic Gastroparesis: A Review.

Authors:  Clipper F Young; Marianne Moussa; Jay H Shubrook
Journal:  Diabetes Spectr       Date:  2020-08

Review 2.  Gastric emptying and glycaemia in health and diabetes mellitus.

Authors:  Liza K Phillips; Adam M Deane; Karen L Jones; Chris K Rayner; Michael Horowitz
Journal:  Nat Rev Endocrinol       Date:  2014-11-25       Impact factor: 43.330

3.  Cytotoxicity of streptozotocin on neuroendocrine cells of the pancreas and the gut.

Authors:  O Brenna; G Qvigstad; E Brenna; H L Waldum
Journal:  Dig Dis Sci       Date:  2003-05       Impact factor: 3.199

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.